AFAntonio Felici

Antonio Felici

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Felici has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Schäublin

    Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    2 shared publications
  • Alexander Alanine

    Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    2 shared publications
  • Andreas Haldimann

    Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    2 shared publications
  • Andrei L. Osterman

    Sanford Burnham Prebys Medical Discovery Institute

    2 shared publications
  • Andrej Trauner

    Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    2 shared publications
  • Carina Cantrill

    Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    2 shared publications

Latest Publications

  • Open Access

    Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter

    by Claudia Zampaloni, Patrizio Mattei, Konrad Bleicher, Lotte Winther, Claudia Thäte, Christian Bucher, Jean-Michel Adam, Alexander Alanine, Kurt E. Amrein, Vadim Baidin, et al.


  • Top Cited Papers
    Open Access

    A novel antibiotic class targeting the lipopolysaccharide transporter

    by Claudia Zampaloni, Patrizio Mattei, Konrad Bleicher, Lotte Winther, Claudia Thäte, Christian Bucher, Jean-Michel Adam, Alexander Alanine, Kurt E. Amrein, Vadim Baidin, et al.

    Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.


  • Open Access

    Mouse pneumonia model by Acinetobacter baumannii multidrug resistant strains: Comparison between intranasal inoculation, intratracheal instillation and oropharyngeal aspiration techniques

    by Gabriella Bergamini, Maria Elisa Perico, Stefano Di Palma, Daniela Sabatini, Filippo Andreetta, Rossella Defazio, Antonio Felici, Livia Ferrari

    Infectious pneumonia induced by multidrug resistant (MDR)Acinetobacter baumanniistrains is among the most common and deadly forms of healthcare acquired infections. Over the years, different strategies have been put in place to increase host susceptibility to MDRA.baumannii, since only a self-limiting pneumonia with no or limited local bacterial replication was frequently obtained in mouse models. Direct instillation into the trachea or intranasal inoculation of the bacterial suspension are the techniques used to induce the infection in most of the preclinical models of pneumonia developed to date. More recently, the oropharyngeal aspiration procedure has been widely described in the literature for a variety of purposes including pathogens administration. Aim of this study was to compare the oropharyngeal aspiration technique to the intranasal inoculation and intratracheal instillation in the ability of inducing a consistent lung infection with two MDRA.baumanniiclinical isolates in immunocompromised mice. Moreover, pneumonia obtained by bacteria administration with two out of three techniques, intratracheal and oropharyngeal, was characterised in terms of histopathology of pulmonary lesions, biomarkers of inflammation level and leukocytes cells infiltration extent after mice treatment with either vehicle or the antibiotic tigecycline. The data generated clearly showed that both strains were not able to colonize the lungs when inoculated by intranasal route. By contrast, the bacterial load in lungs of mice intratracheally or oropharyngeally infected significantly increased during 26 hours of monitoring, thus highlighting the ability of these strains to generate the infection when directly instilled into the lower respiratory airways. Furthermore, the intragroup variability of mice was significantly reduced with respect to those intranasally administered. Tigecycline was efficacious in lung bacterial load and cytokines release reduction. Findings were supported by semi-quantitative histopathological evaluation of the pulmonary lesions and by inflammatory biomarkers analysis. To conclude, both intratracheal instillation and oropharyngeal aspiration techniques showed to be suitable methods for inducing a robust and consistent pneumonia infection in mice when difficult MDRA.baumanniiclinical isolates were used. Noteworthy, oropharyngeal aspiration not requiring specific technical skills and dedicated equipment, was proven to be a safer, easier and faster technique in comparison to the intratracheal instillation.


  • Open Access

    Targeting Cystalysin, a Virulence Factor of Treponema denticola‐Supported Periodontitis

    by Francesca Spyrakis, Barbara Cellini, Stefano Bruno, Paolo Benedetti, Emanuele Carosati, Gabriele Cruciani, Fabrizio Micheli, Antonio Felici, Pietro Cozzini, Glen E. Kellogg, et al.

    Cystalysin from Treponema denticola is a pyridoxal 5′‐phosphate dependent lyase that catalyzes the formation of pyruvate, ammonia, and sulfide from cysteine. It is a virulence factor in adult periodontitis because its reaction contributes to hemolysis, which sustains the pathogen. Therefore, it was proposed as a potential antimicrobial target. To identify specific inhibitors by structure‐based in silico methods, we first validated the crystal structure of cystalysin as a reliable starting point for the design of ligands. By using single‐crystal absorption microspectrophotometry, we found that the enzyme in the crystalline state, with respect to that in solution, exhibits: 1) the same absorption spectra for the catalytic intermediates, 2) a close pKa value for the residue controlling the keto enamine ionization, and 3) similar reactivity with glycine, L‐serine, L‐methionine, and the nonspecific irreversible inhibitor aminoethoxyvinylglycine. Next, we screened in silico a library of 9357 compounds with the Fingerprints for Ligands and Proteins (FLAP) software, by using the three‐dimensional structure of cystalysin as a template. From the library, 17 compounds were selected and experimentally evaluated by enzyme assays and spectroscopic methods. Two compounds were found to competitively inhibit recombinant T. denticola cystalysin, with inhibition constant (Ki) values of 25 and 37 μM. One of them exhibited a minimum inhibitory concentration (MIC) value of 64 μg mL−1 on Moraxella catarrhalis ATCC 23246, which proves its ability to cross bacterial membranes.


  • ChemInform Abstract: New N-Substituted 7-Aminocephalosporanic Acid Derivatives as Potential Agents Against Streptococcus pneumoniae. Synthesis and in vitro Activity.

    by Aldo Balsamo, Silvia Barontini, Federico Calvani, Daniela Gentili, Marco Macchia, Armando Rossello, Enza Di Modugno, Antonio Felici

    ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.